Clopidogrel belongs to a drug that inhibits platelet aggregation and does not belong to the anticoagulant class. Clopidogrel is an antagonist of the P2Y12 receptor on the platelet surface, which can prevent the platelet components within the blood from aggregating together, and has the effect of inhibiting platelet aggregation, thus reducing the chance of thrombosis. Clopidogrel is clinically used for the secondary prevention of atherosclerotic thrombotic events, and is suitable for patients with recent myocardial infarction, patients with recent ischemic stroke, patients with unstable angina or non-Q-wave myocardial infarction, patients with stent placement, and patients with confirmed peripheral arterial disease. As for anticoagulant drugs, they are mainly used to prevent blood clotting in arteries, especially plaque and stenosis sites, and commonly used drugs include low molecular heparin, warfarin, rivaroxaban, and so on. It is mainly used for heart valve diseases, such as rheumatic heart disease, atrial fibrillation, aortic coarctation, as well as long-term bedridden people to prevent lower limb venous thrombosis. In summary, although clopidogrel can also prevent thrombosis, but does not belong to the anticoagulant, and anticoagulant mechanism of action, there are some differences in the indications. The specific use of drugs need to strictly follow the doctor’s instructions.